{"success":true,"data":{"pressRelease":{"id":"154667","rtpr_id":"nPnc7Nz84a-20260928","ticker":"BBNX","exchange":"NASDAQ","all_tickers":["BBNX"],"title":"BBNX Investors Have Opportunity to Lead Beta Bionics, Inc. Securities Fraud Lawsuit","author":"PR Newswire","published_at":"2026-09-28T22:05:00.031Z","article_body":"BBNX Investors Have Opportunity to Lead Beta Bionics, Inc. Securities Fraud Lawsuit\nPR Newswire\n\nNEW YORK, Sept. 28, 2026\n\nNEW YORK, Sept. 28, 2026 /PRNewswire/ --\n\nWhy: Rosen Law Firm, a global investor rights law firm, reminds purchasers of\ncommon stock of Beta Bionics, Inc. (NASDAQ: BBNX) between July 30, 2025 and\nFebruary 24, 2026, both dates inclusive (the \"Class Period\"), of the important\nNovember 3, 2026 lead plaintiff deadline.\n\nSo what: If you purchased Beta Bionics common stock you may be entitled to\ncompensation without payment of any out of pocket fees or costs through a\ncontingency fee arrangement.\n\nWhat to do next: To join the Beta Bionics class action, go to\nhttps://rosenlegal.com/cases/beta-bionics-inc/join\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4784522-1&h=3599080950&u=https%3A%2F%2Frosenlegal.com%2Fcases%2Fbeta-bionics-inc%2Fjoin&a=https%3A%2F%2Frosenlegal.com%2Fcases%2Fbeta-bionics-inc%2Fjoin)\n or call Phillip Kim, Esq. toll-free at 866-767-3653 or email\ncase@rosenlegal.com (mailto:case@rosenlegal.com)  for information on the\nclass action. A class action lawsuit has already been filed. If you wish to\nserve as lead plaintiff, you must move the Court no later than November 3,\n2026. A lead plaintiff is a representative party acting on behalf of other\nclass members in directing the litigation.\n\nWhy Rosen Law: We encourage investors to select qualified counsel with a track\nrecord of success in leadership roles. Often, firms issuing notices do not\nhave comparable experience, resources, or any meaningful peer\nrecognition. Many of these firms do not actually handle securities class\nactions, but are merely middlemen that refer clients or partner with law firms\nthat actually litigate the cases. Be wise in selecting counsel. The Rosen Law\nFirm represents investors throughout the globe, concentrating its practice in\nsecurities class actions and shareholder derivative litigation. Rosen Law Firm\nhas achieved the largest ever securities class action settlement against a\nChinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class\nAction Services for number of securities class action settlements in 2017. The\nfirm has been ranked in the top 4 each year since 2013 and has recovered\nbillions of dollars for investors. In 2019 alone the firm secured over $438\nmillion for investors. In 2020, founding partner Laurence Rosen was named by\nlaw360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been\nrecognized by Lawdragon and Super Lawyers.\n\nDetails of the case: According to the lawsuit, throughout the Class Period,\ndefendants made materially false and misleading statements to the market about\nBeta Bionics' automated insulin delivery system for the treatment of diabetes,\nknown as the iLet Bionic Pancreas insulin pump (\"iLet\"). The FDA had raised\nnumerous serious issues with the iLet device itself, namely that the device\nwas malfunctioning and dosing patients with dangerously high levels of\ninsulin, causing hypoglycemic events. Thus, contrary to defendants' assertions\nthat the complaints back-filed with the FDA pursuant to the Form 483 were of\nno moment and entirely benign, they instead numbered in the thousands and\nincluded hundreds of life-threatening events requiring significant medical\nintervention. Nor was the FDA satisfied with Beta Bionics' response to the\nissue, as Beta Bionics had utterly failed to implement any meaningful\ncorrective actions. When the true details entered the market, the lawsuit\nclaims that investors suffered damages.\n\nTo join the Beta Bionics class action, go to\nhttps://rosenlegal.com/cases/beta-bionics-inc/join\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4784522-1&h=3599080950&u=https%3A%2F%2Frosenlegal.com%2Fcases%2Fbeta-bionics-inc%2Fjoin&a=https%3A%2F%2Frosenlegal.com%2Fcases%2Fbeta-bionics-inc%2Fjoin)\n or call Phillip Kim, Esq. toll-free at 866-767-3653 or email\ncase@rosenlegal.com (mailto:case@rosenlegal.com)  for information on the\nclass action.\n\nNo Class Has Been Certified. Until a class is certified, you are not\nrepresented by counsel unless you retain one. You may select counsel of your\nchoice. You may also remain an absent class member and do nothing at this\npoint. An investor's ability to share in any potential future recovery is not\ndependent upon serving as lead plaintiff.\n\nFollow us for updates on LinkedIn:\nhttps://www.linkedin.com/company/the-rosen-law-firm\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4784522-1&h=4106231903&u=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fthe-rosen-law-firm&a=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fthe-rosen-law-firm)\n, on Twitter: https://twitter.com/rosen_firm\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4784522-1&h=3466881547&u=https%3A%2F%2Ftwitter.com%2Frosen_firm&a=https%3A%2F%2Ftwitter.com%2Frosen_firm)\n or on Facebook: https://www.facebook.com/rosenlawfirm/\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4784522-1&h=1050239782&u=https%3A%2F%2Fwww.facebook.com%2Frosenlawfirm%2F&a=https%3A%2F%2Fwww.facebook.com%2Frosenlawfirm%2F)\n.\n\nAttorney Advertising. Prior results do not guarantee a similar outcome.\n\nContact Information:\n\n     Laurence Rosen, Esq.\n     Phillip Kim, Esq.\n     The Rosen Law Firm, P.A.\n     275 Madison Avenue, 40th Floor\n     New York, NY 10016\n     Tel: (212) 686-1060\n     Toll Free: (866) 767-3653\n     Fax: (212) 202-3827\n     case@rosenlegal.com (mailto:case@rosenlegal.com)\n     www.rosenlegal.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4784522-1&h=2738884039&u=http%3A%2F%2Fwww.rosenlegal.com%2F&a=www.rosenlegal.com)\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/bbnx-investors-have-opportunity-to-lead-beta-bionics-inc-securities-fraud-lawsuit-302891870.html\n(https://www.prnewswire.com/news-releases/bbnx-investors-have-opportunity-to-lead-beta-bionics-inc-securities-fraud-lawsuit-302891870.html)\n\nSOURCE THE ROSEN LAW FIRM, P. A.\n\n\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1118010/Rosen-Law-Firm-Logo.jpg?id=OA2974679\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPnc7Nz84a-20260928","title":"BBNX Investors Have Opportunity to Lead Beta Bionics, Inc. Securities Fraud Lawsuit","author":"PR Newswire","ticker":"BBNX","created":"2026-09-28T22:05:00.031Z","tickers":["BBNX"],"exchange":"NASDAQ","article_body":"BBNX Investors Have Opportunity to Lead Beta Bionics, Inc. Securities Fraud Lawsuit\nPR Newswire\n\nNEW YORK, Sept. 28, 2026\n\nNEW YORK, Sept. 28, 2026 /PRNewswire/ --\n\nWhy: Rosen Law Firm, a global investor rights law firm, reminds purchasers of\ncommon stock of Beta Bionics, Inc. (NASDAQ: BBNX) between July 30, 2025 and\nFebruary 24, 2026, both dates inclusive (the \"Class Period\"), of the important\nNovember 3, 2026 lead plaintiff deadline.\n\nSo what: If you purchased Beta Bionics common stock you may be entitled to\ncompensation without payment of any out of pocket fees or costs through a\ncontingency fee arrangement.\n\nWhat to do next: To join the Beta Bionics class action, go to\nhttps://rosenlegal.com/cases/beta-bionics-inc/join\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4784522-1&h=3599080950&u=https%3A%2F%2Frosenlegal.com%2Fcases%2Fbeta-bionics-inc%2Fjoin&a=https%3A%2F%2Frosenlegal.com%2Fcases%2Fbeta-bionics-inc%2Fjoin)\n or call Phillip Kim, Esq. toll-free at 866-767-3653 or email\ncase@rosenlegal.com (mailto:case@rosenlegal.com)  for information on the\nclass action. A class action lawsuit has already been filed. If you wish to\nserve as lead plaintiff, you must move the Court no later than November 3,\n2026. A lead plaintiff is a representative party acting on behalf of other\nclass members in directing the litigation.\n\nWhy Rosen Law: We encourage investors to select qualified counsel with a track\nrecord of success in leadership roles. Often, firms issuing notices do not\nhave comparable experience, resources, or any meaningful peer\nrecognition. Many of these firms do not actually handle securities class\nactions, but are merely middlemen that refer clients or partner with law firms\nthat actually litigate the cases. Be wise in selecting counsel. The Rosen Law\nFirm represents investors throughout the globe, concentrating its practice in\nsecurities class actions and shareholder derivative litigation. Rosen Law Firm\nhas achieved the largest ever securities class action settlement against a\nChinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class\nAction Services for number of securities class action settlements in 2017. The\nfirm has been ranked in the top 4 each year since 2013 and has recovered\nbillions of dollars for investors. In 2019 alone the firm secured over $438\nmillion for investors. In 2020, founding partner Laurence Rosen was named by\nlaw360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been\nrecognized by Lawdragon and Super Lawyers.\n\nDetails of the case: According to the lawsuit, throughout the Class Period,\ndefendants made materially false and misleading statements to the market about\nBeta Bionics' automated insulin delivery system for the treatment of diabetes,\nknown as the iLet Bionic Pancreas insulin pump (\"iLet\"). The FDA had raised\nnumerous serious issues with the iLet device itself, namely that the device\nwas malfunctioning and dosing patients with dangerously high levels of\ninsulin, causing hypoglycemic events. Thus, contrary to defendants' assertions\nthat the complaints back-filed with the FDA pursuant to the Form 483 were of\nno moment and entirely benign, they instead numbered in the thousands and\nincluded hundreds of life-threatening events requiring significant medical\nintervention. Nor was the FDA satisfied with Beta Bionics' response to the\nissue, as Beta Bionics had utterly failed to implement any meaningful\ncorrective actions. When the true details entered the market, the lawsuit\nclaims that investors suffered damages.\n\nTo join the Beta Bionics class action, go to\nhttps://rosenlegal.com/cases/beta-bionics-inc/join\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4784522-1&h=3599080950&u=https%3A%2F%2Frosenlegal.com%2Fcases%2Fbeta-bionics-inc%2Fjoin&a=https%3A%2F%2Frosenlegal.com%2Fcases%2Fbeta-bionics-inc%2Fjoin)\n or call Phillip Kim, Esq. toll-free at 866-767-3653 or email\ncase@rosenlegal.com (mailto:case@rosenlegal.com)  for information on the\nclass action.\n\nNo Class Has Been Certified. Until a class is certified, you are not\nrepresented by counsel unless you retain one. You may select counsel of your\nchoice. You may also remain an absent class member and do nothing at this\npoint. An investor's ability to share in any potential future recovery is not\ndependent upon serving as lead plaintiff.\n\nFollow us for updates on LinkedIn:\nhttps://www.linkedin.com/company/the-rosen-law-firm\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4784522-1&h=4106231903&u=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fthe-rosen-law-firm&a=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fthe-rosen-law-firm)\n, on Twitter: https://twitter.com/rosen_firm\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4784522-1&h=3466881547&u=https%3A%2F%2Ftwitter.com%2Frosen_firm&a=https%3A%2F%2Ftwitter.com%2Frosen_firm)\n or on Facebook: https://www.facebook.com/rosenlawfirm/\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4784522-1&h=1050239782&u=https%3A%2F%2Fwww.facebook.com%2Frosenlawfirm%2F&a=https%3A%2F%2Fwww.facebook.com%2Frosenlawfirm%2F)\n.\n\nAttorney Advertising. Prior results do not guarantee a similar outcome.\n\nContact Information:\n\n     Laurence Rosen, Esq.\n     Phillip Kim, Esq.\n     The Rosen Law Firm, P.A.\n     275 Madison Avenue, 40th Floor\n     New York, NY 10016\n     Tel: (212) 686-1060\n     Toll Free: (866) 767-3653\n     Fax: (212) 202-3827\n     case@rosenlegal.com (mailto:case@rosenlegal.com)\n     www.rosenlegal.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4784522-1&h=2738884039&u=http%3A%2F%2Fwww.rosenlegal.com%2F&a=www.rosenlegal.com)\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/bbnx-investors-have-opportunity-to-lead-beta-bionics-inc-securities-fraud-lawsuit-302891870.html\n(https://www.prnewswire.com/news-releases/bbnx-investors-have-opportunity-to-lead-beta-bionics-inc-securities-fraud-lawsuit-302891870.html)\n\nSOURCE THE ROSEN LAW FIRM, P. A.\n\n\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1118010/Rosen-Law-Firm-Logo.jpg?id=OA2974679\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-09-28T22:05:00.109940295Z","server_sent_at_ms":1790633100109},"received_at":"2026-09-28T22:05:00.320Z","source_url":"https://www.prnewswire.com/news-releases/bbnx-investors-have-opportunity-to-lead-beta-bionics-inc-securities-fraud-lawsuit-302891870.html"},"analysis":{"id":"143425","press_release_id":"154667","analysis_json":{"redFlags":["underlying allegations cite FDA Form 483 complaints and life-threatening hypoglycemic events tied to the iLet device","regulatory scrutiny of iLet corrective actions could pose material product/regulatory risk for BBNX"],"eventType":"legal_litigation","narrative":"Rosen Law Firm issued a solicitation reminding BBNX purchasers (July 30, 2025 - February 24, 2026 class period) of the November 3, 2026 lead plaintiff deadline in an already-filed securities fraud class action.\n\nThe suit alleges Beta Bionics made misleading statements about the iLet insulin pump, claiming FDA complaints numbered in the thousands and included hundreds of life-threatening hypoglycemic events.\n\nNo class has been certified; this is law-firm marketing rather than an issuer disclosure, so treat as low-signal noise.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm solicitation — suppress, but monitor FDA/iLet regulatory developments."},"keyFigures":{},"quotedText":"","namedEntities":{"people":[{"name":"Phillip Kim","role":"attorney, Rosen Law Firm"},{"name":"Laurence Rosen","role":"founding partner, Rosen Law Firm"}],"products":["iLet Bionic Pancreas insulin pump"],"companies":[{"name":"Beta Bionics, Inc.","ticker":"BBNX","relationship":"issuer/target of class action"},{"name":"Rosen Law Firm","relationship":"plaintiff law firm"}],"dollarAmounts":[{"amount":"$438 million","context":"amount Rosen Law Firm says it secured for investors in 2019 (law-firm marketing)"}]},"materialImpact":{"score":1,"reasoning":"Plaintiff law-firm solicitation by Rosen Law Firm for an already-filed class action; no new issuer disclosure, no certified class, no settlement. The underlying allegations (FDA Form 483 issues with iLet) are pre-existing news."},"tickerRelevance":{"others":[],"primary":"BBNX"},"globalImportance":15,"audienceRelevance":12,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false,"underlyingRegulatoryRisk":"FDA Form 483 allegations re iLet pump"}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Rosen Law Firm issued a solicitation reminding BBNX purchasers (July 30, 2025 - February 24, 2026 class period) of the November 3, 2026 lead plaintiff deadline in an already-filed securities fraud class action.\n\nThe suit alleges Beta Bionics made misleading statements about the iLet insulin pump, claiming FDA complaints numbered in the thousands and included hundreds of life-threatening hypoglycemic events.\n\nNo class has been certified; this is law-firm marketing rather than an issuer disclosure, so treat as low-signal noise.","key_figures":{},"named_entities":{"people":[{"name":"Phillip Kim","role":"attorney, Rosen Law Firm"},{"name":"Laurence Rosen","role":"founding partner, Rosen Law Firm"}],"products":["iLet Bionic Pancreas insulin pump"],"companies":[{"name":"Beta Bionics, Inc.","ticker":"BBNX","relationship":"issuer/target of class action"},{"name":"Rosen Law Firm","relationship":"plaintiff law firm"}],"dollarAmounts":[{"amount":"$438 million","context":"amount Rosen Law Firm says it secured for investors in 2019 (law-firm marketing)"}]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-28T22:05:04.733Z","global_importance":15,"audience_relevance":12,"importance_components":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false,"underlyingRegulatoryRisk":"FDA Form 483 allegations re iLet pump"}},"durationMs":4348,"modelName":"glm-5.3-flashx"}}